拉米夫定联合α-干扰素治疗慢性乙型肝炎临床观察  

A Clinical study of lamivudine and alpha interferon combination treatment for patients with chronic hepatitis B Infection

作　　者：盛镭[1] 卢诚震[1] 张声捷[1] 

机构地区：[1]天津市传染病医院,300192

出　　处：《实用肝脏病杂志》2003年第4期208-209,共2页Journal of Practical Hepatology

摘　　要：目的 观察拉米夫定与α-干扰素治疗慢性乙型肝炎(CHB)的疗效。方法 对32例(CHB患者采用拉米夫定联合α-干扰素(α-IFN)抗病毒治疗。结果 接受联合抗病毒治疗的32例患者6个月内HBV DNA全部转阴,12个月内无反跳病例,与对照组比较有显著性差异(P<0.005);ALT复常率(87.5％),明显高于对照组患者(P<0.005)。结论拉米夫定联合α-IFN治疗CHB近期疗效较好,优于单一用药。Objective To improve the efficacy of treatment against hepatitis B virus(HBV).Methods 32 patients with chronic hepatitis B(CHB)were treated by combination therapy of lamivudine and alpha interferon. Results All 32 patients responded 6 month treatment.After the treatment, serum HBV DNA of all patients became negative;serum ALT normalized in 28 (87.5%). Nobody recurred during 12 month follow-up. Conclusion The comb; nation of lamivudine and interferon-α therapy has a good clinical efficacy for patients with chronic hepatitis B.

关 键 词：慢性乙型肝炎 拉米夫定 Α-干扰素 联合疗法 

分 类 号：R512.62[医药卫生—内科学]